<DOC>
	<DOCNO>NCT02527213</DOCNO>
	<brief_summary>To evaluate efficacy Sodium Thiosulfate ( STS ) compare placebo , reduce analgesic requirement subject calcific uremic arteriolopathy ( CUA ) initial 28-day treatment phase .</brief_summary>
	<brief_title>Randomized Double Blind Placebo Controlled Trial Sodium Thiosulfate Treatment Pain Associated With Calcific Uremic Arteriolopath</brief_title>
	<detailed_description>Efficacy Sodium Thiosulfate ( STS ) compare placebo , reduce analgesic requirement subject calcific uremic arteriolopathy ( CUA ) initial 28-day treatment phase .</detailed_description>
	<mesh_term>Calciphylaxis</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>1 . Males females â‰¥18 year age able give inform consent . 2 . Calcific uremic arteriolopathy ( CUA ) , either newlydiagnosed preexisting , currently STS yet treat STS either pain medication stable pain medication regimen . The diagnosis calciphylaxis make : The follow clinical feature present , two ( 2 ) follow clinical feature typical histopathological finding present . Clinical feature : 1 . A patient chronic hemodialysis chronic kidney disease GFR le 15/ml/min/1.73 m2 2 . More 2 painful nontreatable skin ulcer concomitant painful purpura 3 . Painful nontreatable skin ulcer trunk , extremity , penis concomitant painful purpura Histopathological finding skin biopsy 3 clinical finding present : 1 . Necrosis ulceration skin calcification tunica medium internal elastic membrane small mediumsized arteriole dermis subcutaneous fat essential diagnosis 2 . Concentric stenosis due edematous intimal thickening also see small mediumsized arteriole dermis subcutaneous fat 3 . End stage renal disease ( ESRD ) chronic maintenance hemodialysis . 4 . Willingness undergo washout preexist STS treatment ( require treatment allocation ) continue double blind treatment period 4 week , might receive placebo . 5 . Ability comply study requirement . 1 . History allergic adverse reaction STS 2 . Current treatment STS indication CUA ( e.g . cyanide poison ) 3 . Currently alternative treatment CUA list . Unless treatment discontinue least 1 month prior screen visit . 1 . Steroids 2 . Hyperbaric Oxygen 3 . Bisphosphonates 4 . Pentoxifylline 5 . Tissue Plasminogen Activator 6 . Luciliar sericata larva ( maggot therapy ) 7 . On Cinacalcet treatment CUA ( i.e . cinacalcet either start dose increase appearance lesion ) 4 . Any coexist disease problem make participation study unadvisable patient compromise integrity study 1 . Cirrhosis liver 2 . History congestive heart failure ( New York Heart Association class III IV ) multiple hospital admission ( least 3 admission 6 month ) 3 . Persistent uncontrolled metabolic acidosis 5 . Chronic kidney disease renal transplant patient diagnosis calciphylaxis hemodialysis . 6 . Any disease condition , judgment Investigator , would place subject undue risk enrol trial , cause inability comply trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>